罗格列酮和瑞格列奈治疗2型糖尿病疗效观察

Therapeutic observation of Rosiglitazone and Repaglinide in the treatment of type 2 diabetes mellitus

目的:探讨罗格列酮和瑞格列奈治疗2型糖尿病的疗效。方法:94例2型糖尿病患者口服罗格列酮4mg^8mg,1次/d,瑞格列奈1mg^4mg,3次/d,治疗16周,监测治疗前后空腹、餐后2h血糖(FBG、PBG)、糖化血红蛋白(HbA1c)、空腹血浆胰岛素(FINS)、低密度脂蛋白(LDL)、肝、肾功能。结果:FBG下降4.98mmol/L,PBG下降8.05mmol/L,HbA1c下降1.93%,FINS下降11.0μU/ml,LDL下降0.12mmol/L,较与治疗前均显著下降(P<0.001及P<0.05),且均未发生低血糖事件及肝肾功能异常(P>0.05)。结论:罗格列酮和瑞格列奈治疗2型糖尿病具有降糖、降脂、降低血浆胰岛素水平、安全性及耐受性良好的特点。

Objective To explore the therapeutic effect of Rosigitazone and Repaglinide in treating type 2 diabetes mellitus. Method Fasting plasma glucose （FPG） pre and post medication, postprandial glucose following meal 2 hours later （ PG2H）, glycosylated hemoglo- bin （ GHbA1c）, fasting insulin （FINS）, low density lipoprotein （LDL） and the functions of liver and renal were monitored in 94 type 2 di- abetic patients in 16 weeks by oral hypoglycemie agents of Rosiglitazone （4-8mg,qd） and Repaglinide （1-4mg, tid）. Results The results showed that there were significant decreases in FPG （4.98mmol/L）, PG2H （8.05 mmol/L）, GHbA1c（ 1.93% ）, FINS （11.01μU/ ml） and LDL （0. 12mmol/L） compared to those in pre-medication （P 〈0.001, P〈0.05）. None of hypoglycemic cases and abnormal hepatic and renal functions occurred （P〉0.05）. Conclusion Rosiglitazone and Repaglinide have the features and benefits of lowering plasma glucose, lipid, plasma insulin levels, also oral safety, excellent tolerability.